Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 5/20 | 0.81 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | POLB | P06746 | 4/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.71 |
| ▸ | KIT | P10721 | 1/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.71 |
| ▸ | RELA | Q04206 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 2/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.67 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10031424 | 0.91 | FLT3 (0.84) | FLT3MEN1KMT2AALDH1A1ABCB1 | |
| SCHEMBL739122 | 0.91 | POLB (0.83) | FLT3MEN1KMT2AALDH1A1ABCB1 | |
| SCHEMBL15277726 | 0.90 | FLT3 (0.74) | FLT3MEN1KMT2AALDH1A1ABCB1 | |
| SCHEMBL28945653 | 0.90 | ABCB1 (0.80) | FLT3MEN1KMT2AALDH1A1ABCB1 | |
| Salvigenin SCHEMBL1427018 | 0.90 | FLT3 (1.00) | FLT3MEN1KMT2AALDH1A1ABCB1 | |
| SCHEMBL1976134 | 0.89 | FLT3 (0.76) | FLT3MEN1KMT2AALDH1A1ABCB1 | |
| SCHEMBL15268294 | 0.88 | FLT3 (0.65) | FLT3MEN1KMT2AALDH1A1ABCB1 | |
| SCHEMBL15674607 | 0.88 | ABCB1 (0.81) | FLT3MEN1KMT2AALDH1A1ABCB1 | |
| SCHEMBL30152130 | 0.88 | ABCB1 (0.81) | FLT3MEN1KMT2AALDH1A1ABCB1 | |
| SCHEMBL6242511 | 0.88 | KMT2A (0.81) | FLT3MEN1KMT2AALDH1A1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220054448-A1 | NOVEL POLYMETHOXYFLAVONE COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | NESTLE SA (CH) | 2022-02-24 | — | — | US | claimed |
| EP-3897617-A1 | NOVEL POLYMETHOXYFLAVONE COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2021-10-27 | — | — | EP | claimed |
| CN-113164441-A | Novel polymethoxyflavone compounds for skeletal muscle modulation, methods and uses thereof | 雀巢产品有限公司 | 2021-07-23 | — | — | CN | claimed |
| WO-2020127183-A1 | NOVEL POLYMETHOXYFLAVONE COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2020-06-25 | — | — | WO | claimed |
| EP-2828248-B1 | FLAVONE DERIVATIVES AND THEIR USE | TWINCORE GMBH (DE) | 2019-01-23 | — | — | EP | claimed |
| CN-102578078-B | Frozen stock solution for nerve cells and freezing storage method | 2ND AFFILIATED HOSPITAL OF WENZHOU MEDICAL COLLEGE | 2013-06-19 | — | — | CN | claimed |
| CN-102578078-A | Frozen stock solution for nerve cells and freezing storage method | 2ND AFFILIATED HOSPITAL OF WENZHOU MEDICAL COLLEGE | 2012-07-18 | — | — | CN | claimed |
| WO-2005020881-A2 | COMPOSITIONS OF FLAVONOIDS AND FLAVONOID-CONTAINING EXTRACTS AND THE TREATMENT OF DISEASES | SHANGHAI COMMAN PHARMACEUTICAL CO. (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050049206-A1 | Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases | SHANGHAI COMMAN PHARMACEUTICAL CO. LTD. (CN) | 2005-03-03 | — | — | US | claimed |
| CN-117740961-A | Compound analysis method of liquorice and liquorice probiotics fermentation preparation | 北京中医药大学 | 2024-03-22 | — | — | CN | disclosed |
| US-20220054448-A1 | NOVEL POLYMETHOXYFLAVONE COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | NESTLE SA (CH) | 2022-02-24 | — | — | US | disclosed |
| EP-3897617-A1 | NOVEL POLYMETHOXYFLAVONE COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-113164441-A | Novel polymethoxyflavone compounds for skeletal muscle modulation, methods and uses thereof | 雀巢产品有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020127183-A1 | NOVEL POLYMETHOXYFLAVONE COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2020-06-25 | — | — | WO | disclosed |
| US-20120029066-A1 | USE OF FLAVONES FOR TREATING PSYCHIATRIC DISORDERS WITH SENSORIMOTOR GATING DEFICITS | TAIPEI MEDICAL UNIVERSITY (TW) | 2012-02-02 | — | — | US | disclosed |
| EP-1556031-A4 | CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF | JENKEN BIOSCIENCES INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20060142211-A1 | Chromones and chromone derivatives and uses thereof | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2006-06-29 | — | — | US | disclosed |
| EP-1556031-A2 | CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF | Jenken Bioscience, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050049206-A1 | Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases | SHANGHAI COMMAN PHARMACEUTICAL CO. LTD. (CN) | 2005-03-03 | — | — | US | disclosed |
| WO-2004037193-A2 | CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF | JENKEN BIOSCIENCES, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054448-A1 | NOVEL POLYMETHOXYFLAVONE COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | MYOF, MYLK2, TNNC1 | FLT3 3867/4885MEN1 4626/4885KMT2A 2094/4885 |
| US-20060142211-A1 | Chromones and chromone derivatives and uses thereof | PROC, HMGB1, PYCARD | FLT3 2228/4885MEN1 1195/4885KMT2A 4070/4885 |
| US-20050049206-A1 | Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases | FNTA, COLGALT1, F3 | FLT3 4440/4885MEN1 4807/4885KMT2A 4107/4885 |
| US-20120029066-A1 | USE OF FLAVONES FOR TREATING PSYCHIATRIC DISORDERS WITH SENSORIMOTOR GATING DEFICITS | HTR2C, GRIN2C, HTR5A | FLT3 3391/4885MEN1 4859/4885KMT2A 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.